Retinal Vein Occlusion - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 63 pages report, published by Global Markets Direct

Keywords : Retinal Vein Occlusion Therapeutic Products under Development, Key Players in Retinal Vein Occlusion Therapeutics, Retinal Vein Occlusion Pipeline Overview, Retinal Vein Occlusion Pipeline, Retinal Vein Occlusion Pipeline Assessment

Report ThumbnailSeptember-2013
Retinal Vein Occlusion - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Retinal Vein Occlusion - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinal Vein Occlusion, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion. Retinal Vein Occlusion - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinal Vein Occlusion.
- A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinal Vein Occlusion pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Retinal Vein Occlusion, H2 2013 7
  • Products under Development for Retinal Vein Occlusion - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Retinal Vein Occlusion, H2 2013 7
  • Products under Development for Retinal Vein Occlusion - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • F. Hoffmann-La Roche Ltd., H2 2013 16
  • Allergan, Inc., H2 2013 17
  • pSivida Corp., H2 2013 18
  • NicOx SA, H2 2013 19
  • ThromboGenics NV, H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Retinal Vein Occlusion Therapeutics - Drug Profile Updates 38
  • Retinal Vein Occlusion Therapeutics - Discontinued Products 50
  • Retinal Vein Occlusion Therapeutics - Dormant Products 51
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Retinal Vein Occlusion Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Retinal Vein Occlusion 7
  • Retinal Vein Occlusion Therapeutics under Development by Companies 9
  • Retinal Vein Occlusion Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Retinal Vein Occlusion Therapeutics - Products under Development by Companies 14
  • Retinal Vein Occlusion Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Retinal Vein Occlusion Therapeutics Development 16
  • F. Hoffmann-La Roche Ltd. 16
  • Allergan, Inc. 17
  • pSivida Corp. 18
  • NicOx SA 19
  • ThromboGenics NV 20
  • Retinal Vein Occlusion - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • ranibizumab - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • ocriplasmin - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • fluocinolone acetonide - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • NCX-434 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • AGN-208397 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • NCX-422 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Annexin V Analogues - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Retinal Vein Occlusion Therapeutics - Drug Profile Updates 38
  • Retinal Vein Occlusion Therapeutics - Discontinued Products 50
  • Retinal Vein Occlusion Therapeutics - Dormant Products 51
  • Retinal Vein Occlusion - Product Development Milestones 52
  • Featured News & Press Releases 52
  • May 08, 2013: Novartis Reports New Data On Lucentis At Association For Research In Vision And Ophthalmology Annual Meeting 52
  • Sep 05, 2012: New Data For Novartis Drug Lucentis Confirms Long-term Efficacy And Safety Profile And Benefits Of Individualized Treatment 53
  • Feb 20, 2012: Bayer Announces Positive One Year Results From Phase III Study In Central Retinal Vein Occlusion Of VEGF Trap-Eye 54
  • Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease 56
  • Jan 13, 2012: Genentech Announces First Milestone Payment To ForSight VISION4 For Development Of Sustained Delivery Of Lucentis 57
  • Aug 18, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Retinal Vein Occlusion 58
  • Aug 17, 2011: Regeneron To Present Data From EYLEA Clinical Studies At ASRS 2011 Annual Meeting 59
  • Aug 03, 2011: NICE Gives Positive Recommendation To Dexamethasone For Treatment Of Common Eye Condition In Final Guidance 59
  • Jun 06, 2011: NICE Recommends Allergan's OZURDEX For Treatment Of Retinal Vein Occulsion 60
  • Jun 06, 2011: Novartis Gains European Commission Approval For Lucentis To Treat Vision Loss Due To Macular Edema Secondary To RVO 60
  • Appendix 62
  • Methodology 62
  • Coverage 62
  • Secondary Research 62
  • Primary Research 62
  • Expert Panel Validation 62
  • Contact Us 63
  • Disclaimer 63

Please select a license type

Share

Related Products

Global Markets DirectRetinal Vein Occlusion - Pipeline Review, H2 2013Product ThumbnailRetinal Vein Occlusion - Pipeline Review, H2 2013, Industry ReportProduct #: 113352
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved